From genetic testing to CPR and stroke intensive care, insurer expands coverage across diagnosis, emergency and acute treatment

Kyobo Life's headquarters at Gwanghwamun in Seoul. [Kyobo Life]
Kyobo Life's headquarters at Gwanghwamun in Seoul. [Kyobo Life]

Kyobo Life announced Tuesday it had secured six exclusive-use rights over the past year — the most of any life insurer in the industry. The results reflect the company's effort to incorporate into its products the coverage customers need both at enrollment and throughout treatment, spanning composite underwriting that reduces premium burdens for people with pre-existing conditions, genetic testing, CPR and stroke intensive care unit hospitalization.

According to the Korea Life Insurance Association, Kyobo Life received six newly granted exclusive-use rights between November 2025 and October 2026, the highest count among life insurers. Exclusive-use rights grant an insurer a monopoly on selling a particular insurance product or rider recognized for its originality and utility; other insurers are barred from selling similar products or riders during the designated period.

Most recently, in October, a rider covering national health insurance-reimbursed stroke intensive care unit hospitalization under the Kyobo My Plan Health Insurance II (non-dividend) product received a six-month exclusive-use right. The rider was the first in the industry to separately cover reimbursed stroke intensive care unit stays, filling a coverage gap between general wards and intensive care units. Its development drew on 11 months of work by a dedicated team and consultations with medical experts.

In July, a composite underwriting rider under the Kyobo K-Customized Health Insurance (non-dividend, composite underwriting type) product received a six-month exclusive-use right. The structure — the first of its kind in the industry — allows customers to apply for coverage eligible for standard underwriting through the standard process, while coverage that is difficult to obtain through standard underwriting due to medical history can be applied for through simplified underwriting. This reduces unnecessary premium surcharges and lets customers select the coverage they need.

In February, two riders under the Kyobo My Plan Health Insurance (non-dividend) product — one covering reimbursed CPR and another covering reimbursed defibrillation and electrical cardioversion — each received six-month exclusive-use rights. The riders extend coverage into emergency treatment, protecting against acute cardiac arrest caused not only by disease but also by traffic accidents, falls and other causes. The Kyobo My Plan Health Insurance II (non-dividend) product was subsequently relaunched in September with significantly enhanced coverage and riders.

Kyobo Life also strengthened coverage at the diagnostic stage. In February, a rider for specific uterine disease coverage under the Kyobo Double-Up Women's Health Insurance (non-dividend) product received a six-month exclusive-use right, expanding coverage to include reimbursed ultrasound examinations required to diagnose certain uterine conditions. Last November, a rider covering genetic testing for hereditary women's cancers under the same product received a three-month exclusive-use right — the first in the industry to cover the cost of genetic testing and next-generation sequencing panel tests for the diagnosis and treatment of hereditary women's cancers.

Kyobo Life works through a dedicated team, drawing on medical expert consultations and statistical analysis, to reflect actual diagnostic and treatment practices as well as customers' enrollment circumstances in its products. The approach embodies the company's management philosophy of taking responsibility for customers' coverage from enrollment and policy maintenance through to claims payment.

"As the medical environment and treatment methods change rapidly, the coverage customers need is also evolving," a Kyobo Life official said. "We will continue to introduce products that carefully reflect the difficulties customers face during the treatment process."


won@heraldcorp.com